Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, today announced the completion of a first-in-human feasibility study demonstrating the ability to record key nerve-related biosignals from 16 peripheral nerves in 8 chronic pain patients across multiple anatomical targets.